

## Special Issue

# Precision Medicine in Neurooncology and Neurosurgery for the 21st Century, 2nd Edition

### Message from the Guest Editors

Recent advances in brain tumour imaging, genomics and therapeutic technology are now allowing for a precise and tailored approach to the management of patients with brain tumours. This is essential given the heterogeneity of these tumours as well as the challenges of surgery in eloquent brain which thus far have confounded the outcomes. In this Special Issue, we aim to provide the readers with a comprehensive collection of cutting-edge articles exemplifying this personalised approach to brain tumours. We hope this sharing of ideas will further fuel efforts towards more effective and safer therapies for brain tumours. We would welcome original basic science and clinical research papers and review articles epitomising this ethos. Dr. José Pedro Lavrador

### Guest Editors

Prof. Dr. Keyoumars Ashkan

King's College Hospital NHS Foundation Trust, London, UK

Dr. José Pedro Lavrador

King's College Hospital NHS Foundation Trust, London, UK

### Deadline for manuscript submissions

30 April 2025



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/si/195280](https://mdpi.com/si/195280)

*Journal of Personalized  
Medicine*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://mdpi.com/journal/)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm.mdpi.com)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).